| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3787 |
| Trial ID | NCT06294236 |
| Disease | Lupus Erythematosus | Systemic Lupus Erythematosus | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Granulomatous PolyangIItis | Microscopic PolyangIItis |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | SC291 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM) |
| Year | 2024 |
| Country | United States |
| Company sponsor | Sana Biotechnology |
| Other ID(s) | SC291-102 |
| Cohort 1 | |||||||||||
|
|||||||||||